175 related articles for article (PubMed ID: 24951635)
1. Effect of APOE and CHRNA7 genotypes on the cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.
Braga IL; Silva PN; Furuya TK; Santos LC; Pires BC; Mazzotti DR; Bertolucci PH; Cendoroglo MS; Smith MC
Am J Alzheimers Dis Other Demen; 2015 Mar; 30(2):139-44. PubMed ID: 24951635
[TBL] [Abstract][Full Text] [Related]
2. CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer's disease.
Weng PH; Chen JH; Chen TF; Sun Y; Wen LL; Yip PK; Chu YM; Chen YC
PLoS One; 2013; 8(12):e84059. PubMed ID: 24391883
[TBL] [Abstract][Full Text] [Related]
3. Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitors (AChEI) in Patients with Alzheimer's Disease.
Russo P; Kisialiou A; Moroni R; Prinzi G; Fini M
Curr Drug Targets; 2017; 18(10):1179-1190. PubMed ID: 26424395
[TBL] [Abstract][Full Text] [Related]
4. CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimer's Disease Patients.
Clarelli F; Mascia E; Santangelo R; Mazzeo S; Giacalone G; Galimberti D; Fusco F; Zuffi M; Fenoglio C; Franceschi M; Scarpini E; Forloni G; Magnani G; Comi G; Albani D; Martinelli Boneschi F
J Alzheimers Dis; 2016 Apr; 52(4):1203-8. PubMed ID: 27104904
[TBL] [Abstract][Full Text] [Related]
5. Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.
Patterson CE; Todd SA; Passmore AP
Pharmacogenomics J; 2011 Dec; 11(6):444-50. PubMed ID: 20644562
[TBL] [Abstract][Full Text] [Related]
6. Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.
Wattmo C; Blennow K; Hansson O
BMC Neurol; 2020 Jan; 20(1):10. PubMed ID: 31918679
[TBL] [Abstract][Full Text] [Related]
7. The effect of APOE ε4 allele on cholinesterase inhibitors in patients with Alzheimer disease: evaluation of the feasibility of resting state functional connectivity magnetic resonance imaging.
Wang L; Day J; Roe CM; Brier MR; Thomas JB; Benzinger TL; Morris JC; Ances BM
Alzheimer Dis Assoc Disord; 2014; 28(2):122-7. PubMed ID: 24830360
[TBL] [Abstract][Full Text] [Related]
8. Effect of Apolipoprotein E ɛ4 Carrier Status on Cognitive Response to Acetylcholinesterase Inhibitors in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Cheng YC; Huang YC; Liu HC
Dement Geriatr Cogn Disord; 2018; 45(5-6):335-352. PubMed ID: 30041236
[TBL] [Abstract][Full Text] [Related]
9. CHRNA7 Polymorphisms and Dementia Risk: Interactions with Apolipoprotein ε4 and Cigarette Smoking.
Weng PH; Chen JH; Chen TF; Sun Y; Wen LL; Yip PK; Chu YM; Chen YC
Sci Rep; 2016 Jun; 6():27231. PubMed ID: 27249957
[TBL] [Abstract][Full Text] [Related]
10. Effect of genetic polymorphisms on Alzheimer's disease treatment outcomes: an update.
Sumirtanurdin R; Thalib AY; Cantona K; Abdulah R
Clin Interv Aging; 2019; 14():631-642. PubMed ID: 30992661
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
[TBL] [Abstract][Full Text] [Related]
12. Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
De Beaumont L; Pelleieux S; Lamarre-Théroux L; Dea D; Poirier J;
J Alzheimers Dis; 2016 Oct; 54(3):913-922. PubMed ID: 27567841
[TBL] [Abstract][Full Text] [Related]
13. Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.
Wattmo C; Wallin ÅK
Alzheimers Res Ther; 2017 Aug; 9(1):70. PubMed ID: 28859660
[TBL] [Abstract][Full Text] [Related]
14. Increased Aβ
Wang HY; Trocmé-Thibierge C; Stucky A; Shah SM; Kvasic J; Khan A; Morain P; Guignot I; Bouguen E; Deschet K; Pueyo M; Mocaer E; Ousset PJ; Vellas B; Kiyasova V
Alzheimers Res Ther; 2017 Jul; 9(1):54. PubMed ID: 28750690
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease and mixed dementia: a one-year naturalistic study.
Miranda LF; Gomes KB; Silveira JN; Pianetti GA; Byrro RM; Peles PR; Pereira FH; Santos TR; Assini AG; Ribeiro VV; Tito PA; Matoso RO; Lima TO; Moraes EN; Caramelli P
J Alzheimers Dis; 2015; 45(2):609-20. PubMed ID: 25589728
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacological approaches to the therapy of Alzheimer's disease].
Gavrilova SI
Vestn Ross Akad Med Nauk; 2006; (9-10):30-4. PubMed ID: 17111921
[TBL] [Abstract][Full Text] [Related]
17. Alzheimer's disease: case-control association study of polymorphisms in ACHE, CHAT, and BCHE genes in a Sardinian sample.
Piccardi M; Congiu D; Squassina A; Manconi F; Putzu PF; Mereu RM; Chillotti C; Del Zompo M
Am J Med Genet B Neuropsychiatr Genet; 2007 Oct; 144B(7):895-9. PubMed ID: 17503475
[TBL] [Abstract][Full Text] [Related]
18. Cholinesterase Inhibitors Response Might Be Related to Right Hippocampal Functional Connectivity in Mild Alzheimer's Disease.
Rizzi L; Cardoso Magalhães TN; Lecce N; Dos Santos Moraes A; Fernandes Casseb R; Vieira Ligo Teixeira C; Machado de Campos B; Junqueira Ribeiro de Rezende T; Leme Talib L; Forlenza OV; Cendes F; Balthazar MLF
Brain Connect; 2023 Jun; 13(5):269-274. PubMed ID: 35994390
[No Abstract] [Full Text] [Related]
19. Initial cognitive response to cholinesterase inhibitors and subsequent long-term course in patients with mild Alzheimer's disease.
Droogsma E; van Asselt D; Diekhuis M; Veeger N; van der Hooft C; De Deyn PP
Int Psychogeriatr; 2015 Aug; 27(8):1323-33. PubMed ID: 25779465
[TBL] [Abstract][Full Text] [Related]
20. Regulatory region single nucleotide polymorphisms of the apolipoprotein E gene and the rate of cognitive decline in Alzheimer's disease.
Belbin O; Dunn JL; Ling Y; Morgan L; Chappell S; Beaumont H; Warden D; Smith DA; Kalsheker N; Morgan K
Hum Mol Genet; 2007 Sep; 16(18):2199-208. PubMed ID: 17613540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
